5 completed, 3 recruiting, 2 terminated, 1 active not recruiting. 8 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Completed 2, Terminated 2, Active not recruiting 1 |
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Olatec Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease dapansutrile, placebo - Parkinson Disease | Phase 2 | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 36 | 2026-02-02 | 2026-06-16 |
| Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia Dapansutrile, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Recruiting | Marc Donath | 300 | 2024-07-09 | 2026-02-25 |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Dapansutrile, Placebo Tablet - Acute Gout Flare, Gout Attack | Phase 2 / Phase 3 | Recruiting | Olatec Therapeutics, Inc. | 300 | 2023-01-06 | 2026-03-11 |
| A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Dapansutrile, Pembrolizumab - Melanoma | Phase 1 / Phase 2 | Active not recruiting | April Salama, M.D. | 26 | 2022-09-06 | 2026-02-20 |
| Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome dapansutrile capsules, placebo capsules - Covid19, Cytokine Release Syndrome | Phase 2 | Terminated | Olatec Therapeutics, Inc. | 49 | 2020-09-24 | 2023-04-13 |
| Study of Dapansutrile Capsules in Heart Failure dapansutrile capsules, Placebo capsules - Systolic Heart Failure | Phase 1 | Completed | Olatec Therapeutics, Inc. | 30 | 2018-05-16 | 2020-01-09 |
| Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome dapansutrile - Schnitzler Syndrome | Phase 2 | Terminated | Olatec Therapeutics, Inc. | 2 | 2018-05-15 | 2024-02-02 |
| Phase 1 Safety and PK Study of OLT1177 Capsules OLT1177 Capsules, Placebo Capsules - Healthy Volunteers | Phase 1 | Completed | Olatec Therapeutics, Inc. | 35 | 2014-06-01 | 2015-03-06 |
| Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain Placebo Gel, OLT1177 Gel - Osteoarthritis, Pain | Phase 2 | Completed | Olatec Therapeutics, Inc. | 202 | 2014-04-01 | 2017-10-06 |
| Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee OLT1177 Gel, Placebo gel - Osteoarthritis of the Knee | Phase 2 | Completed | Olatec Therapeutics, Inc. | 79 | 2013-01-01 | 2014-10-06 |
| Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects OLT1177 Gel, Placebo gel - Healthy Volunteers | Phase 1 | Completed | Olatec Therapeutics, Inc. | 36 | 2012-06-01 | 2012-09-06 |
Inflammation (4) · Pain (3) · Arthritis (2) · Osteoarthritis (2) · Arthralgia (1) · Arthritis, Gouty (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Diabetes Mellitus, Type 2 (1) · Gout (1) · Heart Failure (1) · Heart Failure, Systolic (1) · Hyperuricemia (1) · Joint Diseases (1) · Melanoma (1)
dapansutrile (9) · pembrolizumab (1)
United States (8) · France (2) · Netherlands (2) · Switzerland (2) · Belgium (1) · Germany (1) · Israel (1) · Spain (1) · United Kingdom (1)
April Salama (1) · Bruce G. Rankin, D.O., C.P.I (1) · Caroline Williams-Gray, BMBCh MA(Cantab) FRCP PhD (1) · Curt Scribner, MD (1) · Jaime A. Pachon, MD (1) · Marc Y. Donath, Prof. (1) · Terry M Jones, MD (1) · Terry M Jones, MD, FAAD (1) · Treva W. Tyson, MD (1) · William Cunningham, MD, FAAD (1)
2023 (1)